A novel necroptosis signature for predicting survival in lung adenocarcinoma.
Immune checkpoint
LUAD
Necroptosis
Prediction
Prognosis
Signature
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
05
06
2023
accepted:
22
11
2023
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
To explore the necroptosis-related genes (NRGs) signature and its predictive values in lung adenocarcinoma (LUAD). The training cohort consisted of tumor samples from The Cancer Genome Atlas, and the validation set comprised data from the Gene Expression Omnibus. Univariate and multivariate Cox regression analyses were applied to identify the prognostic NRG signature as an independent molecular indicator. Correlation analysis was used for the association assessment between the NRG signature and immune checkpoint molecules. NRGs involved in necroptosis and immune NOD-like receptor signaling. The NRG signature based on eight NRGs can divide tumors into high-risk and low-risk groups, which was significantly associated with worse survival. Multivariate Cox regression analysis showed that this NRG signature remained an independent prognostic indicator. Stratification analyses demonstrated that this NRG signature was still effective for predicting survival in each stratum of age, gender, and tumor stage. The ROC curve showed a good predictive ability using the NRG signature in the validation cohort (AUC = 0.81). The NRG signature was related to immune checkpoint molecules PD - 1, PD-L1, and PD-L2. The NRG signature could be a novel predictor of the prognosis and may become a potential therapeutic target in LUAD.
Sections du résumé
BACKGROUND
BACKGROUND
To explore the necroptosis-related genes (NRGs) signature and its predictive values in lung adenocarcinoma (LUAD).
METHODS
METHODS
The training cohort consisted of tumor samples from The Cancer Genome Atlas, and the validation set comprised data from the Gene Expression Omnibus. Univariate and multivariate Cox regression analyses were applied to identify the prognostic NRG signature as an independent molecular indicator. Correlation analysis was used for the association assessment between the NRG signature and immune checkpoint molecules.
RESULTS
RESULTS
NRGs involved in necroptosis and immune NOD-like receptor signaling. The NRG signature based on eight NRGs can divide tumors into high-risk and low-risk groups, which was significantly associated with worse survival. Multivariate Cox regression analysis showed that this NRG signature remained an independent prognostic indicator. Stratification analyses demonstrated that this NRG signature was still effective for predicting survival in each stratum of age, gender, and tumor stage. The ROC curve showed a good predictive ability using the NRG signature in the validation cohort (AUC = 0.81). The NRG signature was related to immune checkpoint molecules PD - 1, PD-L1, and PD-L2.
CONCLUSIONS
CONCLUSIONS
The NRG signature could be a novel predictor of the prognosis and may become a potential therapeutic target in LUAD.
Identifiants
pubmed: 38017445
doi: 10.1186/s12920-023-01748-9
pii: 10.1186/s12920-023-01748-9
pmc: PMC10685572
doi:
Substances chimiques
Immune Checkpoint Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
305Informations de copyright
© 2023. The Author(s).
Références
J Clin Oncol. 2022 Feb 20;40(6):546-555
pubmed: 34985966
Trends Mol Med. 2019 Jul;25(7):585-594
pubmed: 31155338
Trends Cancer. 2022 Jan;8(1):21-27
pubmed: 34627742
Nature. 2015 Jan 15;517(7534):311-20
pubmed: 25592536
Theranostics. 2022 Jan 1;12(2):817-841
pubmed: 34976215
J Clin Lab Anal. 2022 Apr;36(4):e24302
pubmed: 35229919
Front Genet. 2022 Feb 16;13:842218
pubmed: 35251139
J Thorac Dis. 2019 Sep;11(9):3973-3979
pubmed: 31656671
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Lab Invest. 2022 May;102(5):524-533
pubmed: 35022505
Nat Rev Mol Cell Biol. 2017 Feb;18(2):127-136
pubmed: 27999438
Oncol Lett. 2021 Oct;22(4):731
pubmed: 34429771
Cell Oncol (Dordr). 2015 Apr;38(2):93-109
pubmed: 25563586
Front Genet. 2022 Jun 16;13:909245
pubmed: 35783272
Clin Transl Oncol. 2022 Sep;24(9):1785-1799
pubmed: 35486222
Cancer Lett. 2020 Apr 10;475:109-118
pubmed: 32004572
Lancet Oncol. 2015 Jul;16(7):e342-51
pubmed: 26149886
Surg Today. 2018 Jan;48(1):1-8
pubmed: 28280984
Int J Med Sci. 2020 Apr 6;17(8):995-1005
pubmed: 32410828
Front Oncol. 2022 Jul 28;12:955186
pubmed: 35965497
Front Immunol. 2021 Dec 14;12:789610
pubmed: 34970269
BMJ. 2021 Nov 9;375:n2363
pubmed: 34753715
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2022 Aug 2;12(1):13290
pubmed: 35918354
Front Immunol. 2022 May 12;13:897356
pubmed: 35634336
Chin Clin Oncol. 2020 Jun;9(3):27
pubmed: 32192349
Nat Rev Genet. 2021 Aug;22(8):483-501
pubmed: 33762738
Cell Metab. 2020 Sep 1;32(3):420-436.e12
pubmed: 32768387
FEBS J. 2019 Feb;286(3):507-522
pubmed: 30576068
Oncol Lett. 2019 Nov;18(5):4691-4702
pubmed: 31611978
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Nat Rev Cancer. 2013 Oct;13(10):685-700
pubmed: 24060861
Front Immunol. 2022 Jun 24;13:894718
pubmed: 35812403
Cancer Med. 2021 Jan;10(1):3-14
pubmed: 33230935
Biochem Cell Biol. 2020 Oct;98(5):565-574
pubmed: 32191839
Nat Med. 2021 Mar;27(3):491-503
pubmed: 33619369
Mol Cancer. 2019 May 23;18(1):100
pubmed: 31122251
Nat Med. 2018 Oct;24(10):1545-1549
pubmed: 30127394